GPP
Great Point Partners Portfolio holdings
AUM
$154M
1-Year Return
2.36%
This Quarter Return
-4.37%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$522M
AUM Growth
-$120M
(-19%)
Cap. Flow
-$79.9M
Cap. Flow
% of AUM
-15.31%
Top 10 Holdings %
Top 10 Hldgs %
58.05%
Holding
42
New
7
Increased
15
Reduced
8
Closed
9
Top Buys
| 1 |
Merus
MRUS
|
$17.8M |
| 2 |
KalVista Pharmaceuticals
KALV
|
$15.8M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$15.7M |
| 4 |
Context Therapeutics
CNTX
|
$14.9M |
| 5 |
Cytokinetics
CYTK
|
$14.7M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$44.7M |
| 2 |
Insmed
INSM
|
$35.2M |
| 3 |
Apogee Therapeutics
APGE
|
$26.6M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$26.2M |
| 5 |
AnaptysBio
ANAB
|
$23.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
TScan Therapeutics
TCRX
$107M
| $5.5M | 1.05% |
+940,831
| New | +$5.5M |
|
27
VistaGen Therapeutics
VTGN
$111M
| $5.32M | 1.02% |
1,529,338
-329,397
| -18% | -$1.15M |
|
|
BBOT
28
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$798M
| $5.11M | 0.98% |
500,000
| – | – |
|
29
Puma Biotechnology
PBYI
$257M
| $4.85M | 0.93% |
1,486,544
+142,916
| +11% | +$466K |
|
30
Kyverna Therapeutics
KYTX
$157M
| $3.74M | 0.72% |
499,152
+349,152
| +233% | +$2.62M |
|
31
Spyre Therapeutics
SYRE
$1.03B
| $3.16M | 0.61% |
134,612
+9,612
| +8% | +$226K |
|
|
32
AnaptysBio
ANAB
$590M
| $627K | 0.12% |
25,000
-951,981
| -97% | -$23.9M |
|
33
Lexicon Pharmaceuticals
LXRX
$389M
| $50.4K | 0.01% |
+30,000
| New | +$50.4K |
|
|
34
Apogee Therapeutics
APGE
$2.21B
| – | – |
-400,000
| Closed | -$26.6M |
|
35
Arvinas
ARVN
$559M
| – | – |
-71,113
| Closed | -$2.94M |
|
|
JBIO
36
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| – | – |
-25,363
| Closed | -$26.2M |
|
37
Immunocore
IMCR
$1.78B
| – | – |
-115,000
| Closed | -$7.48M |
|
38
MindMed
MNMD
$702M
| – | – |
-2,000,000
| Closed | -$18.8M |
|
39
Ocular Therapeutix
OCUL
$2.21B
| – | – |
-1,728,723
| Closed | -$15.7M |
|
40
Xenon Pharmaceuticals
XENE
$2.98B
| – | – |
-456,148
| Closed | -$19.6M |
|
|
ITCI
41
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-150,000
| Closed | -$10.4M |
|
|
ALPN
42
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – |
-1,128,499
| Closed | -$44.7M |
|